Literature DB >> 22488219

Pretransplant HLA mistyping in diagnostic samples of acute myeloid leukemia patients due to acquired uniparental disomy.

V Dubois1, F Sloan-Béna, A Cesbron, B G Hepkema, K Gagne, S Gimelli, D Heim, A Tichelli, J Delaunay, M Drouet, S Jendly, J Villard, J-M Tiercy.   

Abstract

Although acquired uniparental disomy (aUPD) has been reported in relapse acute myeloid leukemia (AML), pretransplant aUPD involving chromosome 6 is poorly documented. Such events could be of interest because loss of heterozygosity (LOH) resulting from aUPD in leukemic cells may lead to erroneous results if HLA typing for hematopoietic stem cell donor searches is performed on blood samples drawn during blastic crisis. We report here six AML patients whose HLA typing was performed on DNA extracted from peripheral blood obtained at diagnosis. We observed LOH involving the entire HLA region (three patients), HLA-A, B, C (two patients) and HLA-A only (one patient). An array-comparative genomic hybridization showed that copy number was neutral for all loci, thus revealing partial aUPD of chromosome 6p21. When HLA typing was performed on remission blood samples both haplotypes were detected. A 3-4% LOH incidence was estimated in AML patients with high blast counts. Based on DNA mixing experiments, we determined by PCR sequence-specific oligonucleotide hybridization on microbeads arrays a detection threshold for HLA-A, B, DRB1 heterozygosity in blood samples with <80% blasts. Because aUPD may be partial, any homozygous HLA result should be confirmed by a second typing performed on buccal swabs or on blood samples from the patient in remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488219     DOI: 10.1038/leu.2012.68

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Erroneous HLA typing as a result of acquired uniparental disomy in a patient with acute lymphoblastic leukaemia in peripheral blood complete remission.

Authors:  Andrea Bontadini; Sandra Iannelli; Fiorenza Fruet; Simonetta Capelli; Riccardo Masetti; Valérie Dubois; Jean-Marie Tiercy; Arcangelo Prete
Journal:  Blood Transfus       Date:  2015-01-29       Impact factor: 3.443

2.  Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization.

Authors:  D Grosso; E Johnson; B Colombe; O Alpdogan; M Carabasi; J Filicko-O'Hara; S Gaballa; M Kasner; T Klumpp; U Martinez-Outschoorn; J L Wagner; M Weiss; Z Wang; N Flomenberg
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

3.  Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?

Authors:  A Hamdi; K Cao; L M Poon; F Aung; S Kornblau; M A Fernandez Vina; R E Champlin; S O Ciurea
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.

Authors:  Judith Reina-Castillón; Roser Pujol; Marcos López-Sánchez; Benjamín Rodríguez-Santiago; Miriam Aza-Carmona; Juan Ramón González; José Antonio Casado; Juan Antonio Bueren; Julián Sevilla; Isabel Badel; Albert Català; Cristina Beléndez; María Ángeles Dasí; Cristina Díaz de Heredia; Jean Soulier; Detlev Schindler; Luis Alberto Pérez-Jurado; Jordi Surrallés
Journal:  Blood Adv       Date:  2017-01-23

5.  Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.

Authors:  L Crucitti; R Crocchiolo; C Toffalori; B Mazzi; R Greco; A Signori; F Sizzano; L Chiesa; E Zino; M T Lupo Stanghellini; A Assanelli; M G Carrabba; S Marktel; M Marcatti; C Bordignon; C Corti; M Bernardi; J Peccatori; C Bonini; K Fleischhauer; F Ciceri; L Vago
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

6.  Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.

Authors:  Max Jan; Matthew J Leventhal; Elizabeth A Morgan; Jordan C Wengrod; Anwesha Nag; Samantha D Drinan; Bruce M Wollison; Matthew D Ducar; Aaron R Thorner; Scott Leppanen; Jane Baronas; Jonathan Stevens; William J Lane; Natasha Kekre; Vincent T Ho; John Koreth; Corey S Cutler; Sarah Nikiforow; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz; R Coleman Lindsley; Benjamin L Ebert
Journal:  Blood Adv       Date:  2019-07-23

7.  Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.

Authors:  Klaus Witter; Roland Reibke; Marion Subklewe; Robert Zahn; Teresa Kauke; Karsten Spiekermann; Michael Spannagl; Johanna Tischer; Wolfgang Hiddemann; Andrea Dick
Journal:  Bone Marrow Res       Date:  2014-04-03

8.  [Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation].

Authors:  H W Wu; Y M Zhao; H Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-10-14

Review 9.  60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Authors:  Nicoletta Cieri; Katie Maurer; Catherine J Wu
Journal:  Cancer Res       Date:  2021-06-09       Impact factor: 12.701

Review 10.  Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.

Authors:  Pier Edoardo Rovatti; Valentina Gambacorta; Francesca Lorentino; Fabio Ciceri; Luca Vago
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.